Drug Profile
Research programme: respiratory virus inhibitor - Vybion
Alternative Names: Respiratory virus inhibitor research programme - Viral Therapeutics; VirusorbLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Vybion
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Aerosol)
- 20 Jun 2008 Merdian Bioscience acquires recombinant proteins portfolio from Vybion
- 14 May 2008 Vybion executes a letter of intent to sell its recombinant protein business to Meridian Bioscience